News
EC Approves AbbVie’s TEPKINLY Plus R2 for Relapsed or Refractory Follicular Lymphoma
AbbVie’s TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific antibody-based therapy approved in Europe for second-line treatment of relapsed or refractory follicular lymphoma, providing a chemotherapy-free treatment option.
imphoenix82
- July 7, 2026
- 0 Comments
- 17 Views
-
